You are here:

valganciclovir (Valcyte)


Following a full submission:

valganciclovir (Valcyte®): is accepted for restricted use within NHS Scotland.

Indication under review: prevention of cytomegalovirus (CMV) disease in CMV negative patients who have received a solid organ transplant from a CMV positive donor. The marketing authorisation has been amended to allow the duration of CMV prophylaxis in kidney transplant patients to be increased from 100 days to 200 days post-transplantation

SMC restriction: valganciclovir should be initiated by physicians experienced in the care of post-transplant patients.  In a randomised controlled study there was a significant reduction in the incidence of CMV disease at 12 months following 200-day versus 100-day prophylaxis.

Drug Details

Drug Name: valganciclovir (Valcyte)
SMC Drug ID: 662/10
Manufacturer: Roche
Indication: Prevention of cetomegalovirus (CMV) disease in CMV-negative patients who have received a solid organ transplant from CMV-positive donor
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 17 January 2011